

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT
ON-MARKET REPURCHASE OF SHARES**

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”) related to repurchase of shares.

The board of directors of the Company (the “**Board**”) hereby announces that on 14 September 2018 the Company repurchased 1,506,000 shares of the Company (the “**Shares**”) (the “**Share Repurchase**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to the general mandate to buy back the Shares (the “**Repurchase Mandate**”) granted by the shareholders of the Company (the “**Shareholders**”) to the Board at the annual general meeting on the Company held on 1 June 2018. Up to the date of this announcement, the Company has repurchased a total of 1,660,000 of its own Shares pursuant to the Repurchase Mandate. The Company will subsequently cancel the repurchased Shares.

The business operation and financial position of the Company is solid and healthy currently. The Board believes the Share Repurchase can improve the return to the Shareholders. The Board also believes that the Share Repurchase reflects the Company's confidence in its long term business prospects and would ultimately create value for the Company and the Shareholders. The Company may make further share repurchases. Shareholders and investors should note that whether the Company will make any further share repurchases under the Repurchase Mandate or not will be subject to market conditions and the Board's discretion. There is no assurance of the timing, quantity or price of further share repurchases or whether the Company will make further share repurchases. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 14 September 2018

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.

* *For identification purposes only*